

Beginning mid-2020, pharmaceutical manufacturers started overcharging covered entities (CEs) on 340B drugs shipped to CE contract pharmacies. This chart serves as a summary and timeline of these manufacturer restrictions.

Manufacturer Name	Type of Restriction	Who it Applies to	Effective Date
Eli Lilly	Refusing 340B pricing for drugs dispensed at contract pharmacies; recent changes allow 340B pricing if CEs submit contract pharmacy claims data. Any covered entity that doesn't have an in-house pharmacy can choose a single location contract pharmacy .	All covered entities (CEs)	September 1, 2020
AstraZeneca	Refusing 340B pricing for drugs dispensed at contract pharmacies. May designate a single contract pharmacy but each parent site can have one pharmacy site for itself.	All CEs	October 1, 2020
Sanofi	Refusing 340B pricing for drugs dispensed at contract pharmacies if 340B contract pharmacy claims data are not submitted. Any covered entity that doesn't have an in-house pharmacy can choose a single location contract pharmacy .	5 CE types: Consol, CHC, CAH, DSH, RRC, SCH	October 1, 2020
Novartis	Refusing 340B pricing for drugs shipped to contract pharmacies more than 40 miles away from hospitals' parent sites	Hospitals only	November 16, 2020
Novo Nordisk	Refusing 340B pricing for drugs shipped to contract pharmacies.	Hospitals only	January 1, 2021



Manufacturer Name	Type of Restriction	Who it Applies to	Effective Date
	<u>Can designate two contract pharmacies to receive 340B drugs</u> (one specialty, one regular)		
United Therapeutics	Phase 1: Orders for contract pharmacy drugs accepted only if CE made a “valid 340B purchase” during first three quarters of 2020. <u>Phase 2:</u> Then, refusing 340B pricing for drugs dispensed at all contract pharmacies, unless CE submits claims data.	All CEs	Phase 1: November 20, 2020 Phase 2: December 1, 2021
Boehringer Ingelheim	Will ship 340B drugs only to CEs and their child sites. Any covered entity that does not have an in-house pharmacy <u>can choose one contract pharmacy to receive 340B drugs.</u>	Hospitals only	August 1, 2021
Merck	Refusing 340B pricing for drugs dispensed at contract pharmacies if 340B contract pharmacy claims data are not submitted. Any covered entity that does not have an in-house pharmacy <u>can elect one contract pharmacy at a single location.</u>	Hospitals, CHCs	September 1, 2021 As of May 31, 2022: Includes health centers
UCB	Will provide 340B priced drugs to locations registered as 340B covered entities or child sites. Any covered entity that does not have an in-house pharmacy <u>can elect one contract pharmacy at a single location.</u>	Hospitals only	December 13, 2021
Amgen	Refusing 340B pricing for drugs dispensed at contract pharmacies	Hospitals only	January 3, 2022



Manufacturer Name	Type of Restriction	Who it Applies to	Effective Date
	if 340B contract pharmacy claims data are not submitted. Any covered entity that does not have an in-house pharmacy can elect one contract pharmacy at a single location (single HIN)		
AbbVie	Refusing 340B pricing for drugs dispensed at contract pharmacies if 340B contract pharmacy claims data are not submitted. Any covered entity that does not have an in-house pharmacy can elect one contract pharmacy at a single location.	Hospitals only	February 1, 2022
Pfizer	Refusing 340B pricing for drugs dispensed at contract pharmacies if 340B contract pharmacy claims data are not submitted. Any covered entity that does not have an in-house pharmacy can elect one contract pharmacy at a single location (single HIN)	Hospitals only	March 1, 2022
Bristol Myers Squibb	Refusing 340B pricing for “non-IMiD” (Immunomodulatory imide drug) products dispensed at contract pharmacies; modifying access to 340B pricing under IMiD limited distribution network. Will recognize up to 2 contract pharmacies (one for non-IMiDs, another for IMiDs).	Hospitals for non-IMiDs; All CEs for IMiDs	March 1, 2022
GlaxoSmithKline	Refusing 340B pricing for drugs dispensed at contract pharmacies if 340B contract pharmacy claims data are not submitted. Any	Hospitals only	April 1, 2022



Manufacturer Name	Type of Restriction	Who it Applies to	Effective Date
	covered entity that does not have an in-house pharmacy can designate one contract pharmacy location (single HIN) to have drugs shipped to.		
Gilead	Refusing 340B pricing for brand-name Hepatitis C drugs dispensed at contract pharmacies if 340B contract pharmacy claims data are not submitted. Any covered entity that does not have an in-house pharmacy may designate a single contract pharmacy location . Likewise, this update does not apply to contract pharmacies that are wholly owned by a covered entity or health system.	All CEs	May 2, 2022
Johnson & Johnson	Refusing 340B pricing for drugs dispensed at contract pharmacies; specifically: immunosuppressants, monoclonal antibodies, blood thinners, and treatments for diabetes, cancer, HIV, mental disorders, pulmonary arterial hypertension, and chemotherapy-induced anemia. If they choose not to submit data, may still designate a single contract pharmacy location (single HIN) .	Hospitals only	May 2, 2022
Exelixis	Refusing 340B pricing for drugs dispensed at contract pharmacies, specifically Cometriq and Cabometyx (cancer drugs). If	Hospitals only; grantees exempt “until further notice”	July 6, 2022



Manufacturer Name	Type of Restriction	Who it Applies to	Effective Date
	they choose not to submit data, may still designate a single contract pharmacy location (single HIN) .		
Bausch	Refusing 340B pricing for drugs dispensed at contract pharmacies if 340B contract pharmacy claims data are not submitted. Any covered entity that does not have an in-house pharmacy can elect one contract pharmacy at a single location (single HIN)	All CEs	August 1, 2022